The purpose of this study is to define the absorption, breakdown and excretion of a single dose of radiolabelled SB-649868 and its breakdown products by measuring their concentration in blood, urine and faeces over a 7-10 day period. "Radiolabelled" means that the test drug has a radioactive component to help us track the drug. The safety and tolerability of the test drug will also be assessed.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
8
SB-649868 will be provided as powder in a bottle which will be reconstituted into a solution prior to dosing via a hard gelatin capsule. Each subject will receive one unit dose of SB-649868 30 milligram reconstituted powder presented in a size 00 capsule once. The capsule will be swallowed with 160 milliliters of water.
GSK Investigational Site
Tranent, West Lothian, United Kingdom
Excretion of SB649868 by measuring radioactivity in urine and faeces
Time frame: over 7-10 days.
Plasma levels of SB-649868 by measuring drug levels and radioactivity in plasma. Plasma, urine,faeces samples to study the metabolites of SB649868.
Time frame: over 4 days
Safety and tolerability of 14C-SB649868 by adverse event monitoring, lab samples and cardiovascular monitoring.
Time frame: over the course of the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.